Jim Cramer Sees Amgen's Underappreciated Repatha as a Market Rival to Eli Lilly's GLP-1 Opportunity

Amgen's stock has surged in 2026, rising about 31% so far this year. According to CNBC's Jim Cramer, one key driver of this increase is Amgen's underappreciated Repatha drug. In a recent segment, Cramer highlighted the cardiovascular benefits of Repatha and its potential to rival Eli Lilly's massive GLP-1 market opportunity.

Cramer described Repatha as 'a shot that you take every other week' which reduces the risk of death by 20% in people with high risk for heart attack or stroke. He also noted its effectiveness against diabetes and high cholesterol. Additionally, Cramer pointed out that cardiologists are increasingly pushing LDL cholesterol levels as low as possible, expanding the pool of potential patients for Repatha.

Repatha sales jumped 37% to $953 million in Q2 2026, with new-to-brand prescriptions growing over 50% year-over-year. Amgen CEO Robert A. Bradway attributed this growth to expanded cardiologist use and adoption by primary-care physicians treating high-risk patients.